Literature DB >> 17159617

The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility.

Youngjee Choi1, John C Novak, Ashleigh Hillier, Nicholas A Votolato, David Q Beversdorf.   

Abstract

BACKGROUND: The noradrenergic system modulates cognitive flexibility for insight-based problem solving in studies using beta-adrenergic antagonists, which block noradrenergic neurotransmission postsynaptically. However, it is not known whether alpha2-adrenergic agonists, that decrease noradrenergic neurotransmission by presynaptic inhibition, have the same effect.
OBJECTIVES: Therefore, we wished to test whether alpha2-adrenergic agonists would have a similar effect on cognitive flexibility.
METHODS: Eighteen normal adults were tested on cognitive flexibility, problem solving, verbal and spatial memory tasks after receiving clonidine (0.1 mg), an alpha2-agonist, placebo, or ephedrine (25 mg), a noradrenergic stimulant.
RESULTS: Three-way analysis of variance revealed no significant drug effect on cognitive flexibility or problem solving. There was also no significant effect of clonidine on memory.
CONCLUSIONS: Therefore, alpha2-agonists do not influence cognitive flexibility in the same manner as beta-antagonists. Better performance on memory with clonidine might be expected based on primate studies demonstrating benefits in working memory using clonidine. This benefit was not observed for the commonly used clinical memory tasks in our study. This may have implications for why clonidine has not demonstrated efficacy for cognitive disorders such as Alzheimer disease, despite its known benefit for working memory in animal models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17159617     DOI: 10.1097/01.wnn.0000213919.95266.0d

Source DB:  PubMed          Journal:  Cogn Behav Neurol        ISSN: 1543-3633            Impact factor:   1.600


  10 in total

Review 1.  A neurochemical yin and yang: does serotonin activate and norepinephrine deactivate the prefrontal cortex?

Authors:  Paul J Fitzgerald
Journal:  Psychopharmacology (Berl)       Date:  2010-04-13       Impact factor: 4.530

2.  Neuropsychopharmacological regulation of performance on creativity-related tasks.

Authors:  David Q Beversdorf
Journal:  Curr Opin Behav Sci       Date:  2018-09-27

Review 3.  Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.

Authors:  L Cinnamon Bidwell; Rachel E Dew; Scott H Kollins
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

4.  Muscarinic and Nicotinic Modulation of Memory but not Verbal Problem-solving.

Authors:  Shawn F Smyth; David Q Beversdorf
Journal:  Cogn Behav Neurol       Date:  2019-12       Impact factor: 1.600

Review 5.  Cognitive enhancers for the treatment of ADHD.

Authors:  L Cinnamon Bidwell; F Joseph McClernon; Scott H Kollins
Journal:  Pharmacol Biochem Behav       Date:  2011-05-10       Impact factor: 3.533

6.  Protracted cognitive effects produced by clonidine in Macaca nemestrina performing a delayed matching task.

Authors:  Jerry J Buccafusco; Scott J Webster; Alvin V Terry; Nancy Kille; Donna Blessing
Journal:  Psychopharmacology (Berl)       Date:  2008-09-11       Impact factor: 4.530

Review 7.  The Role of the Noradrenergic System in Autism Spectrum Disorders, Implications for Treatment.

Authors:  David Q Beversdorf
Journal:  Semin Pediatr Neurol       Date:  2020-06-24       Impact factor: 1.636

8.  Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

Authors:  Diane E May; Christopher J Kratochvil
Journal:  Drugs       Date:  2010       Impact factor: 9.546

Review 9.  Linking ADHD to the Neural Circuitry of Attention.

Authors:  Adrienne Mueller; David S Hong; Steven Shepard; Tirin Moore
Journal:  Trends Cogn Sci       Date:  2017-05-05       Impact factor: 20.229

10.  Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial.

Authors:  Mayur B Patel; John W McKenna; JoAnn M Alvarez; Ayaka Sugiura; Judith M Jenkins; Oscar D Guillamondegui; Pratik P Pandharipande
Journal:  Trials       Date:  2012-09-26       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.